Cerus Corp. (CERS)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$2.59+0.78%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · CERS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -25.4% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 99.5% |
Growth built into the price is above our model estimate.
The price assumes 124.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 88 industry peers · Company calendar date is not available
CERS — earnings in line
Dated 2026-07-30
as Exhibit 99.1 hereto. The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company…
Why it matters: Confirming the raised guidance shows strong demand and growth momentum for Cerus.
Supportive ifQ2 product revenue reported between $227 million and $231 million.
Worry ifQ2 product revenue falls below $227 million.
Why it matters: Improving cash flow shows better financial health and operational efficiency. It is crucial for future growth.
Supportive ifCash from operations turns positive in the next report.
Worry ifCash from operations stays negative or gets worse in the next report.
Why it matters: A buyback program can signal management's confidence in the company's future. It may also support the stock price.
Supportive ifA public announcement that shares details of the buyback program.
Worry ifNo announcement of a buyback program by the next earnings call.
Why it matters: Better cash flow means better efficiency and financial health.
Supportive ifCash from operations is positive in Q2.
Worry ifCash from operations is still negative in Q2.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$208 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $634 loss on $10,000 · 6.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,832 loss on $10,000 · 38.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Higher operating costs may show problems and hurt profits.
Worry ifTotal operating expenses rise more than 5% from last year.
Less concerning ifTotal operating expenses stay the same or drop from last year.
Why it matters: Positive net income shows a turnaround in making money. This is important for investor trust.
Supportive ifNet income turns positive in the next earnings report.
Worry ifNet income remains negative or worsens in the next earnings report.
Why it matters: Improved cash flow shows the company is managing its costs better. It can lead to more investment opportunities.
Supportive ifCash from operating activities increases by more than 10% in the next quarter.
Worry ifCash from operating activities goes down or stays the same next quarter.
Why it matters: The results will impact the future of the INTERCEPT RBC system and Cerus's growth.
Watch forThe Phase 3 RedeS trial shows good results for safety and effectiveness.
Also watch forThe Phase 3 RedeS trial shows bad results for safety or effectiveness.
Why it matters: Having positive net income is key for long-term success. It shows financial health.
Supportive ifNet income turns positive from -$1.64M in 2026-Q1.
Worry ifNet income remains negative or worsens in the next quarter.
Why it matters: Updates on the review show progress for Cerus's main product.
Supportive ifRegulators gave good feedback on the INTERCEPT RBC system.
Worry ifThere are delays or bad feedback from regulators about the INTERCEPT RBC system.
Why it matters: If product revenue growth slows, it may signal challenges in maintaining momentum. This could impact investor confidence.
Worry ifQ3 product revenue growth is below 10% year over year.
Less concerning ifQ3 product revenue growth is 10% or higher year over year.
Why it matters: Higher operating costs may show problems and hurt profits. This could worry investors.
Worry ifOperating costs are more than $37 million in Q3.
Less concerning ifOperating expenses stay at or below $37 million in Q3.
Why it matters: A quick FDA decision is important for Cerus' product plans and growth.
Watch forFDA decision on INT200 PMA submission is positive, allowing for product launch.
Also watch forFDA decision on INT200 PMA submission is delayed or negative.
Why it matters: Strong IFC sales would show that management's growth plan works and help revenue.
Supportive ifIFC sales exceed $25 million for the full year 2026.
Worry ifIFC sales fall below $23 million for the full year 2026.